Search Results - "Bravatà, I."

P.08.17 MUCOSAL HEALING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ANTI-TNF ALPHA by Bravatà, I, Cappello, M, Calvaruso, V, Attardo, S, Peralta, S

Get full text

P.06.19 LONG TERM ADALIMUMAB EFFICACY IN STEROID-DEPENDENT CROHN'S DISEASE PATIENTS by Orlando, A, Renna, S, Mocciaro, F, Cappello, M, Bravatà, I, Di Mitri, R, Craxi, A, Cottone, M

Get full text

P.08.8 PERSONALITY FACTORS AND PERCEPTION OF QUALITY OF LIFE (HRQOL) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) AND MATCHED CONTROLS by Cappello, M, Nastri, L, Bravatà, I, Massihnia, E, Rumeo, M.V, La Barbera, D, Craxì, A

Get full text

P.1.173: FORMATION OF NON-ORGAN SPECIFIC AUTOANTIBODIES (NOSA) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) TREATED WITH ANTI-TUMOR NECROSIS FACTOR-ALPHA AGENTS by Bravatà, I, Cappello, M, Randazzo, C, Licata, A, Barbaria, F, Almasio, P.L, Craxì, A

Get full text

P.1.221: SERUM LIPID ALTERATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH TNF ALPHA ANTAGONISTS by Amato, L, Cappello, M, Bravatà, I, Randazzo, C, Almasio, P.L, Craxì, A

Get full text

P.1.124: DISEASE EXTENTION IS THE MAJOR PROGNOSTIC FACTOR OF CLINICAL COURSE IN PATIENTS WITH ULCERATIVE COLITIS by Mazza, M, Cappello, M, Almasio, P.L, Peralta, S, Bravatà, I, Craxì, A

Get full text

P.16.18 PERSONALITY PROFILE, DEFENSE MECHANISMS AND PERCEPTION OF QUALITY OF LIFE (QOL) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): USEFULNESS OF AN INTEGRATED APPROACH by Cappello, M, Nastri, L, Bravatà, I, Bonanno, B, Frenda, M, Massihnia, E, Morgante, M.C, Rumeo, M.V, Vanella, F, La Barbera, D, Craxì, A

Get full text

P.67 THROMBOPHILIA IN INFLAMMATORY BOWEL DISEASE: WHAT IS THE IMPACT OF GENETIC FACTORS? by Cappello, M, Bravatà, I, Randazzo, C, Grimaudo, S, Pipitone, R, Di Cristina, A, Licata, A, Cammà, C, Craxì, A

Get full text

Golimumab: clinical update on its use for ulcerative colitis by Gilardi, D, Fiorino, G, Allocca, M, Bravatà, I, Danese, S

“…Monoclonal antibodies directed against tumor necrosis factor alpha (anti-TNF-α agents) have dramatically changed the therapeutical approach to inflammatory…”
Get full text

RWD113 Switching to TNFi Versus Non-TNFi Biologics in Ulcerative Colitis Patients: Real-World Outcomes from a German Claims Data Analysis by Zhuleku, E., Wirth, D., Nissinen, R., Passey, A., Bravatà, I., Ziavra, D., Duva, A., Lee, J., Maywald, U., Wilke, T., Bokemeyer, B.

Get full text

P091 Switching to TNFi versus non-TNFi biologics in Crohn’s Disease patients: Real-world outcomes from a German claims data analysis by Antolin-Fontes, B, Borsi, A, Nissinen, R, Bravatà, I, Barthelmes, J N, Le Bars, M, Lee, J, Maywald, U, Bokemeyer, B, Wilke, T, Ghiani, M

Get full text

DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial by Peyrin-Biroulet, L, Vermeire, S, D’Haens, G R, Panés, J, Dignass, A, Magro, F, Le Bars, M, Lahaye, M, Nazar, M, Ni, L, Bravatà, I, Lavie, F, Daperno, M, Lukáš, M, Armuzzi, A, Löwenberg, M, Gaya, D R, Danese, S

Get full text

OP35 Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn’s Disease - Week 48 analysis of the STARDUST trial by Danese, S, Vermeire, S, D’Haens, G, Panés, J, Dignass, A, Magro, F, Nazar, M, Le Bars, M, Lahaye, M, Ni, L, Bravatà, I, Gaya, D R, Peyrin-Biroulet, L

Get full text

OP40 Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn’s Disease patients in the STARDUST trial by Danese, S, Vermeire, S, Dignass, A, Panés, J, D’Haens, G, Magro, F, Le Bars, M, Nazar, M, Lahaye, M, Ni, L, Bravatà, I, Gaya, D R, Peyrin-Biroulet, L

Get full text

P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn’s disease: results up to Week 48 of the STARDUST trial by Danese, S, Vermeire, S, D’Haens, G, Panés, J, Dignass, A, Magro, F, Nazar, M, Le Bars, M, Lahaye, M, Ni, L, Bravatà, I, Gaya, D R, Peyrin-Biroulet, L

Get full text

P180 Non-invasive assessment of cardiovascular risk in young patients with inflammatory bowel disease (IBD) compared with healthy controls (HC) by Cappello, M., Bravatà, I., Aiello, A., Calvaruso, V., Torres, D., Tuttolomondo, A., Licata, A., Craxì, A., Cammà, C.

Get full text

P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials by Peyrin-Biroulet, L, Panaccione, R, Gasink, C, Hoops, T, Izanec, J L, Ma, T, Nazar, M, Bravata, I, Lahaye, M, Irving, P M, Loftus, E V, Danese, S, Sands, B E

Get full text